Recent advances in brain tumor therapy: Local intracerebral drug delivery by polymers

Christopher Guerin, Alessandro Olivi, Jon David Weingart, H. Christopher Lawson, Henry Brem

Research output: Contribution to journalArticle

Abstract

New approaches to malignant glioma are being actively investigated. Local drug delivery directly to the site of the tumor is one novel approach that has been approved by the US FDA and other regulatory agencies worldwide. This agent, Gliadel®, delivers the chemotherapeutic drug carmustine (BCNU) from a biodegradable polymer placed in the resection cavity after brain tumor surgery. Gliadel® represents the first clinical application of polymer delivery for brain tumors, but the potential for this new methodology is far greater. In this review, we will briefly summarize the development of Gliadel® from a laboratory idea to its current role as an approved treatment for gliomas. Then we will present the most recent work being done to expand the potential benefits of polymeric delivery for brain tumors. This work includes trials for its use as the initial therapy for gliomas, as well as its use against metastasis. Further clinical trials exploring the maximum-tolerated dose and the combination of Gliadel® with systemic chemotherapeutic treatments such as temozolamide and O6-benzylguanine will be reviewed. Finally, we will present preclinical work on the efficacy of polymeric methods for delivering other chemotherapeutic agents, and a variety of novel compounds that modify brain tumor biology. This latter work represents potential future clinical applications of local polymeric drug delivery to the brain and other sites where cancers can occur.

Original languageEnglish (US)
Pages (from-to)27-37
Number of pages11
JournalInvestigational New Drugs
Volume22
Issue number1
DOIs
StatePublished - Jan 2004

Fingerprint

Brain Neoplasms
Polymers
Glioma
Carmustine
Pharmaceutical Preparations
Maximum Tolerated Dose
Therapeutics
Neoplasms
Clinical Trials
Neoplasm Metastasis
poliferprosan 20 drug combination carmustine
Brain

Keywords

  • Angiogenesis
  • Chemotherapy
  • Gliadel®
  • Immunotherapy
  • Interstitial therapy
  • Radiosensitizers

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this

Recent advances in brain tumor therapy : Local intracerebral drug delivery by polymers. / Guerin, Christopher; Olivi, Alessandro; Weingart, Jon David; Lawson, H. Christopher; Brem, Henry.

In: Investigational New Drugs, Vol. 22, No. 1, 01.2004, p. 27-37.

Research output: Contribution to journalArticle

Guerin, Christopher ; Olivi, Alessandro ; Weingart, Jon David ; Lawson, H. Christopher ; Brem, Henry. / Recent advances in brain tumor therapy : Local intracerebral drug delivery by polymers. In: Investigational New Drugs. 2004 ; Vol. 22, No. 1. pp. 27-37.
@article{e223396aedb24509800bfcb59b99fa0d,
title = "Recent advances in brain tumor therapy: Local intracerebral drug delivery by polymers",
abstract = "New approaches to malignant glioma are being actively investigated. Local drug delivery directly to the site of the tumor is one novel approach that has been approved by the US FDA and other regulatory agencies worldwide. This agent, Gliadel{\circledR}, delivers the chemotherapeutic drug carmustine (BCNU) from a biodegradable polymer placed in the resection cavity after brain tumor surgery. Gliadel{\circledR} represents the first clinical application of polymer delivery for brain tumors, but the potential for this new methodology is far greater. In this review, we will briefly summarize the development of Gliadel{\circledR} from a laboratory idea to its current role as an approved treatment for gliomas. Then we will present the most recent work being done to expand the potential benefits of polymeric delivery for brain tumors. This work includes trials for its use as the initial therapy for gliomas, as well as its use against metastasis. Further clinical trials exploring the maximum-tolerated dose and the combination of Gliadel{\circledR} with systemic chemotherapeutic treatments such as temozolamide and O6-benzylguanine will be reviewed. Finally, we will present preclinical work on the efficacy of polymeric methods for delivering other chemotherapeutic agents, and a variety of novel compounds that modify brain tumor biology. This latter work represents potential future clinical applications of local polymeric drug delivery to the brain and other sites where cancers can occur.",
keywords = "Angiogenesis, Chemotherapy, Gliadel{\circledR}, Immunotherapy, Interstitial therapy, Radiosensitizers",
author = "Christopher Guerin and Alessandro Olivi and Weingart, {Jon David} and Lawson, {H. Christopher} and Henry Brem",
year = "2004",
month = "1",
doi = "10.1023/B:DRUG.0000006172.65135.3e",
language = "English (US)",
volume = "22",
pages = "27--37",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "1",

}

TY - JOUR

T1 - Recent advances in brain tumor therapy

T2 - Local intracerebral drug delivery by polymers

AU - Guerin, Christopher

AU - Olivi, Alessandro

AU - Weingart, Jon David

AU - Lawson, H. Christopher

AU - Brem, Henry

PY - 2004/1

Y1 - 2004/1

N2 - New approaches to malignant glioma are being actively investigated. Local drug delivery directly to the site of the tumor is one novel approach that has been approved by the US FDA and other regulatory agencies worldwide. This agent, Gliadel®, delivers the chemotherapeutic drug carmustine (BCNU) from a biodegradable polymer placed in the resection cavity after brain tumor surgery. Gliadel® represents the first clinical application of polymer delivery for brain tumors, but the potential for this new methodology is far greater. In this review, we will briefly summarize the development of Gliadel® from a laboratory idea to its current role as an approved treatment for gliomas. Then we will present the most recent work being done to expand the potential benefits of polymeric delivery for brain tumors. This work includes trials for its use as the initial therapy for gliomas, as well as its use against metastasis. Further clinical trials exploring the maximum-tolerated dose and the combination of Gliadel® with systemic chemotherapeutic treatments such as temozolamide and O6-benzylguanine will be reviewed. Finally, we will present preclinical work on the efficacy of polymeric methods for delivering other chemotherapeutic agents, and a variety of novel compounds that modify brain tumor biology. This latter work represents potential future clinical applications of local polymeric drug delivery to the brain and other sites where cancers can occur.

AB - New approaches to malignant glioma are being actively investigated. Local drug delivery directly to the site of the tumor is one novel approach that has been approved by the US FDA and other regulatory agencies worldwide. This agent, Gliadel®, delivers the chemotherapeutic drug carmustine (BCNU) from a biodegradable polymer placed in the resection cavity after brain tumor surgery. Gliadel® represents the first clinical application of polymer delivery for brain tumors, but the potential for this new methodology is far greater. In this review, we will briefly summarize the development of Gliadel® from a laboratory idea to its current role as an approved treatment for gliomas. Then we will present the most recent work being done to expand the potential benefits of polymeric delivery for brain tumors. This work includes trials for its use as the initial therapy for gliomas, as well as its use against metastasis. Further clinical trials exploring the maximum-tolerated dose and the combination of Gliadel® with systemic chemotherapeutic treatments such as temozolamide and O6-benzylguanine will be reviewed. Finally, we will present preclinical work on the efficacy of polymeric methods for delivering other chemotherapeutic agents, and a variety of novel compounds that modify brain tumor biology. This latter work represents potential future clinical applications of local polymeric drug delivery to the brain and other sites where cancers can occur.

KW - Angiogenesis

KW - Chemotherapy

KW - Gliadel®

KW - Immunotherapy

KW - Interstitial therapy

KW - Radiosensitizers

UR - http://www.scopus.com/inward/record.url?scp=1042291304&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1042291304&partnerID=8YFLogxK

U2 - 10.1023/B:DRUG.0000006172.65135.3e

DO - 10.1023/B:DRUG.0000006172.65135.3e

M3 - Article

C2 - 14707492

AN - SCOPUS:1042291304

VL - 22

SP - 27

EP - 37

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 1

ER -